Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study

Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study

Introduction Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12–20% of generalised MG (gMG) patients despite immunotherapies. Plasma exchange (PLEX) transiently depletes pathogenic mediators, while neonatal Fc receptor antagonists (e...

Full description

Saved in:
Bibliographic Details
Main Authors: Lu Zhang, Kan Wang, Yong Hao, Yangtai Guan, Jing Peng, Li Gao, Song Gao, Qiuju Li, Chong Xie, Yuhui Wang, Yanan Wu, Mengze Zhang, Xiaokun Wang, Chunran Xue, Yiwei Yang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:BMJ Neurology Open
Online Access:https://neurologyopen.bmj.com/content/7/2/e001180.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://neurologyopen.bmj.com/content/7/2/e001180.full

Similar Items